A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
The investigators primary objective is to determine the safety and toxicity of incorporating
blinatumomab into the post-allogeneic hematopoietic stem cell transplant (HSCT) maintenance
setting for patients with CD19+-B-cell malignancies (Acute Lymphoblastic Leukemia [ALL],
Non-Hodgkin's Lymphoma [NHL]).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins